Alta Partners

Alta Partners is a leading healthcare-focused venture capital firm dedicated to empowering the next generation of healthcare. The firm invests in early-stage biotechnology, life sciences, and technology-enabled healthcare services companies. They aim to partner with entrepreneurs who are building high-impact companies that challenge the status quo and provide better outcomes for patients by integrating physicians, payers, and patients through technology and innovation.

Founded in 1996, Alta Partners was established by four senior partners from Burr, Egan, Deleage & Co.: Jean Deleage, Guy Nohra, Garrett Gruener, and Marino Polestra. Burr, Egan, Deleage & Co. was a pioneering venture capital firm with a focus on early-stage investments in life sciences, information technology, and communications. Over its first decade, Alta Partners successfully raised eight venture funds, accumulating over $2 billion in assets under management. In 2017, Pete Hudson and Bob More joined the firm, leading to the launch of the Alta Partners NextGen Funds, which now total over $800 million across four tailored portfolios.

Alta Partners boasts a robust portfolio with a strong track record, having contributed to over 75 FDA-approved products and 119 mergers, acquisitions, and IPOs. Notable investments include companies like Kelonia Therapeutics, eGenesis, Tyra Biosciences, Variant Bio, Be Biopharma, Vir Biotechnology, Allakos, and DispatchHealth. These companies span various areas within healthcare, from developing novel therapeutics and gene therapies to pioneering home-based care delivery platforms and solutions for infectious diseases.

The investment team at Alta Partners brings decades of collective experience in venture capital, investment banking, operations, and healthcare delivery. They are described as dedicated entrepreneurs, seasoned investors, and trusted partners who take active roles in building companies. Key team members include Managing Directors Dan Janney, Pete Hudson, M.D., and Bob More, along with Chief Financial Officer Larry Randall. The firm emphasizes a long investment horizon and a hands-on approach, working closely with their portfolio companies on the frontlines.